TX-MAVENIR/XILINX
13.4.2021 15:02:05 CEST | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), and Xilinx, Inc. (NASDAQ: XLNX), the leader in adaptive computing, announced today the companies are collaborating to bring to market a unified 4G/5G O-RAN massive MIMO (mMIMO) portfolio to enable Open RAN deployments. The first mMIMO 64TRX joint solution is expected to be available in Q4 2021.
Working together, the two companies have successfully completed end-to-end integration of a first-generation mMIMO solution using Open RAN principles. Held at the Mavenir Lab in Bangalore, India, the integration covered multiple deployment scenarios and was evaluated by six CSPs, all leading global operators. Mavenir delivered the Virtualized RAN (vRAN) support for mMIMO, including Core Network, CU and DU, with Xilinx providing the Category B O-RAN Radio Unit.
“This integration demonstrates an efficient Open RAN massive MIMO solution to achieve diversification of the telecommunications supply chain,” says Pardeep Kohli, President and CEO, Mavenir. “This is an important milestone in the delivery of open and interoperable interfaces enabling the deployment of mMIMO in high density, high mobile traffic metro areas.”
“We were early proponents of Open RAN technology along with Mavenir and actively led in standards development in the industry through many field trials around the world,” said Liam Madden, executive vice president and general manager, Wired and Wireless Group at Xilinx. “With the investment we have done on our market-leading wireless radio technology and massive MIMO R&D, we are excited to collaborate with Mavenir to bring our collective technology and radio system expertise together that will accelerate the deployment of market leading 5G O-RAN massive MIMO radio solutions.”
With history of leadership success in various 4G and 5G network deployments worldwide, the companies are jointly developing the next generation of mMIMO products which will bring the world’s first O-RAN compliant 64TRX mMIMO products that support up to 400MHz instantaneous bandwidth in a compact form factor. Mavenir's vRAN software supports Multi-User MIMO with up to 16 layers, advanced receiver algorithms, full digital beamforming - all running on Mavenir's open and flexible cloud-native platform, as well as on other cloud platforms.
These products will leverage Xilinx’s technology platform including RFSoC DFE and Versal AI for advanced beamforming, delivering a fully integrated hardware and software O-RAN compliant mMIMO solution.
“5G Open RAN has significant momentum in the market with ABI Research forecasting network vendor spending to reach $10 billion by 2026-27 and then surpass traditional RAN at $30 billion by 2030,” said Dimitris Mavrakis, senior research director of 5G at ABI Research. “As Mavenir and Xilinx continue to work together to accelerate O-RAN-based massive MIMO adoption, their solutions will be well-timed to serve this high-growth market with the higher spectral efficiency, performance, power efficiency and cost needed as 5G demand intensifies.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Xilinx:
Xilinx, Inc. develops highly flexible and adaptive processing platforms that enable rapid innovation across a variety of technologies - from the cloud, to the edge, to the endpoint. Xilinx is the inventor of the FPGA and Adaptive SoCs (including our Adaptive Compute Acceleration Platform, or ACAP), designed to deliver the most dynamic computing technology in the industry. We collaborate with our customers to create scalable, differentiated and intelligent solutions that enable the adaptable, intelligent and connected world of the future. For more information, visit xilinx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005187/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom